Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients

The choice between Basiliximab (BSX) or Anti-Thymocyte Globulin (ATG) as induction therapy in non-immunized kidney transplant recipients remains uncertain. Whilst ATG may allow steroid withdrawal and a decrease in tacrolimus, it also increases infectious complications. We investigated outcomes in no...

Descripción completa

Detalles Bibliográficos
Autores principales: Masset, Christophe, Kerleau, Clarisse, Blancho, Gilles, Hourmant, Maryvonne, Walencik, Alexandre, Ville, Simon, Kervella, Delphine, Cantarovich, Diego, Houzet, Aurélie, Giral, Magali, Garandeau, Claire, Dantal, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Health Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935561/
https://www.ncbi.nlm.nih.gov/pubmed/36819125
http://dx.doi.org/10.3389/ti.2023.10816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935561/
https://www.ncbi.nlm.nih.gov/pubmed/36819125
http://dx.doi.org/10.3389/ti.2023.10816

Ejemplares similares